Delivering Leading-Edge Cancer Expertise

The Mattson Jack Group, Inc. (MattsonJack) is unmatched in offering its oncology clients unique quantitative and qualitative insights into the complex oncology healthcare market. MattsonJack combines strategic and tactical marketing skills with extensive technical and clinical expertise - focusing on the rapidly changing cancer care environment and related therapeutic areas.

MattsonJack integrates primary research conducted in the United States, Europe and Japan into business and technological evaluations for single-client projects and retainer-based consultation.

What MattsonJack's oncology specialists offer clients:

• more than 150 total years of healthcare and cancer experience
  
• international and domestic expertise
  
• customized consulting approaches
  
• skillful primary research
  
• innovative analytical approaches
  
• unique modeling methodologies
  
• in-depth syndicated reports
  
• special pricing for small companies
  

MattsonJack provides value to many divisions and job levels within a pharmaceutical or biotechnology company:

• product managers (global and domestic)
  
• business development executives
  
• business unit leaders
  
• sales and marketing managers
  
• reimbursement and managed care teams

MattsonJack's Comprehensive Approach to Oncology Custom-Consulting

MattsonJack's expertise in oncology enables us to take a multidisciplinary approach to pharmaceutical consulting and to develop integrated solutions for our clients. Our industry, consulting, and international experiences qualify our consulting specialists to conduct engagements in the following areas

Custom-Consulting Engagement Formats

Market Research Products with Inquiry Support

• Provides the benefits of major market research efforts
• Tested models, patient and product summaries, and forecasts
• Focus on emerging technologies, patient populations, treatment patterns, marketing and sales dynamics, and future forecast

Single-Client Private Consulting

• Provides customized, independent, third-party assessment of clients’ business issues
• Clients meet with a MattsonJack team leader to monitor engagement progress and timeliness and evaluate the need to shift the focus of study based on interim results

Retainer-based Consulting

• Provides specific quantity of professional time over a defined course of time
• Ideal for companies with quick turnaround inquiries and general market research, management, and planning assignments
• Clients are provided a primary liaison at MattsonJack who coordinates tasks, reports to client, reviews all materials sent, and ensures quick response

Proprietary Modeling for Oncology

MattsonJack has developed a number of proprietary models that it employs in its multiclient reports and in single client assignments that include both qualitative and quantitative methodologies. For more information on how MattsonJack can develop models to meet your needs, phone (650) 212-7010 or e-mail info@mattsonjack.com.

Cancer Economics Model examines the indirect and direct costs of cancer by incorporating the various components of cancer spending (e.g., magnitude of the disease, research and development expenditures, payer funding, and direct provider and drug costs) into a unified model.
 
Emerging Technology Valuation Mode assigns a commercial viability score to a new or pipeline product based on an assessment of key success factors, commercial development potential and timeline, competitive environment, and forecasted indications, treatment populations, pricing, and revenue.
 
Future Outlook Scenarios Model postulates three or four alternative scenarios for the future of a market, product, or business. In a workshop format, a team of experts identifies high-impact / high-uncertainty—factors and signposts of change that help guide business decisions.
 
Indication Prioritization Ranking Model is a quantitative assessment process to rank a cancer indication taking into account current management trends, unmet needs, patient population sizes, and products in development. These criteria are weighted to generate an overall rank score to assist in indication prioritization based on unmet needs.
 
Market Evolution Model considers and weights factors such as patient populations, patient influence, reimbursement influencers, provider trends, current management practices, emerging technologies, and existing and emerging competition to develop forecasts of the market potential and product opportunities in specific therapeutic arenas relevant to pharmaceutical manufacturers.
 
Patient Decision Model guides one through the spectrum of cancer care that a patient traverses from symptoms to diagnosis to treatment and follow up to recovery or death.
 
Relapse and Remission Mode estimates the reintroduction of relapsing patients into the treatment population and removes those patients who are estimated to achieve a long-term remission (greater than five years). This model utilizes treatment data to estimate the different untreated, responding, and nonresponding patient groups. The responding patient subgroup is then modeled to account for the duration of remission and the reentrance of patients into the treatment setting.
 
Severity and Opportunity Ranking Model utilizes stage-specific relative survival to calculate a severity of disease ranking. This ranking reflects current unmet needs and limitations of current therapeutic options. Combining the Severity Scores with MattsonJack's 5-year Prevalence by Stage populations allows for the calculation of an Opportunity Score, which appropriately weights the unmet need compared to the size of the patient population.
 
Stakeholder Influence Models evaluate the level of influence that key stakeholders and other factors in the delivery of care have on the physician specialist’s treatment patterns, prescribing patterns, and drug choices.
 
Time to Progression Model predicts the time it takes for a cancer patient to progress from one stage of disease to the next through MattsonJack's unique calculations that have been affirmed by leading cancer epidemiologists.
 
Treatable Universe Model accounts for patients receiving first- and second-line therapy, nonresponders, relapsing patients, and patients in long-term remission.
 
Treatment Algorithms by Stage illustrate first-line and second-line treatments by cancer stage and estimate first-line response and average duration of first response.

CancerMPact®

Supportive Care Perspectives™

Oncology Marketing Strategies™ U.S. / Western Europe

Future Focus™: Myelodysplastic Syndromes (U.S.)™

CancerNSight™

These ongoing, comprehensive studies provide insights into the current and future cancer dynamics in the U.S. and important international markets that are of key interest to market researchers. Dedicated chapters provide rich evaluations of patient populations, stakeholder trends, reimbursement influencers, clinical management, and emerging technologies, as well as detailed market models. These reports are viewed as the "gold standards" for oncology market assessments.

For more information on MattsonJack services or products, phone (650) 403-7001, (314) 469-7600 or e-mail info@mattsonjack.com